Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock is a Buy.

Oscar Health (NYSE: OSCR) built on its profitable start to 2025 with a strong first quarter, though emerging challenges in Q2 ...

HDFC Securities downgrades Eris to Add from Buy, as the strong run-up in the stock price factors in near-term triggers.

Novo Nordisk NVO -1.23% Get Free Report has outperformed the market over the past 5 years by 1.33% on an annualized basis producing an average annual return of 15.96%. Currently, Novo Nordisk has a ...

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Pharmaceutical tariffs are coming, part of President Trump’s stated goal of bringing drug manufacturing back to the U.S.

Mr. Nader Kabbani is a Chief Operating Officer at Hims & Hers Health, Inc.